Glaukos Corp Stock Price, News & Analysis

Glaukos Corporation (NYSE: GKOS) announced positive results from its Phase 3 trial of iLink™ Epi-on therapy for treating keratoconus. The trial met its primary efficacy endpoint, showing a statistically significant improvement in maximum corneal curvature (Kmax) at 6 months. The treatment group exhibited a Kmax improvement of -1.0D (p = 0.0004), indicating the therapy's effectiveness. With 98% of placebo patients opting for Epi-on after the trial, safety was affirmed as 97% completed the study. Glaukos aims for FDA submission in 2022 and anticipates approval in 2023, capitalizing on this promising therapy.

Glaukos Corporation (NYSE: GKOS) will announce its fourth quarter and full year 2020 financial results on February 25, 2021, after market closure. A conference call to discuss these results will take place at 1:30 p.m. PST (4:30 p.m. EST) on the same day. Investors can access the live webcast through the company’s website. Glaukos specializes in innovative treatments for glaucoma and other ocular conditions, having pioneered Micro-Invasive Glaucoma Surgery (MIGS) with devices such as the iStent® and iStent inject®.

Glaukos Corporation (NYSE: GKOS) announced promising 12-month data from its U.S. Investigational Device Exemption pivotal trial for the iStent infinite Trabecular Micro-Bypass System, indicating significant effectiveness in lowering intraocular pressure (IOP) in patients with open-angle glaucoma. In the trial, 76% of participants experienced a 20% or greater reduction in mean IOP, with over 50% achieving a ≥30% reduction. The study reported a favorable safety profile, with no serious complications noted. Glaukos plans to submit for FDA approval of the device, aiming for a late 2021 target.

Glaukos Corporation (GKOS) announced positive interim results from its 24-month Phase 2b trial of the iDose^® TR implant for glaucoma treatment. The trial, involving 154 subjects, showed sustained reductions in intraocular pressure (IOP) with average decreases of 7.9 mmHg and 7.4 mmHg for fast- and slow-release arms, respectively, compared to 7.8 mmHg for the timolol control. The implant aims to offer a durable alternative to daily eye drops. Glaukos is focused on completing enrollment for the Phase 3 trials, targeting FDA approval for 2023.

Glaukos Corporation (NYSE: GKOS) announced preliminary, unaudited net sales for Q4 and the full year ending December 31, 2020. Q4 net sales are estimated at $73 million, with $58 million from Glaucoma and $15 million from Corneal Health. For the full year, net sales are projected at $225 million, driven by $179 million in Glaucoma and $46 million in Corneal Health. CEO Thomas Burns acknowledged the team's efforts amidst COVID-19 challenges and expressed confidence in the company's future, although caution remains due to ongoing uncertainties. Final results will be available in late February.

Glaukos Corporation (NYSE: GKOS) announced its management will participate virtually in the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 11:00 a.m. PST. Investors can access a live and archived webcast on the company's website. Glaukos focuses on innovative therapies for glaucoma and other ophthalmic conditions, having pioneered Micro-Invasive Glaucoma Surgery (MIGS) with its iStent® devices launched since 2012. The company's technology aims to transform glaucoma treatment and enhance corneal health through specialized pharmaceuticals and surgical therapies.

Glaukos Corporation (NYSE: GKOS), a leader in ophthalmic medical technology, announced its participation in upcoming investor conferences. These include the Berenberg U.S. CEO Conference on November 12, 2020, the Stephens Annual Investment Conference on November 19, 2020, and the Piper Sandler 32nd Annual Healthcare Conference with events on November 23 and December 2, 2020. Live webcasts of these events will be accessible on Glaukos' investor website. Glaukos focuses on innovative therapies for glaucoma and corneal disorders, pioneering Micro-Invasive Glaucoma Surgery.

Glaukos Corporation (NYSE: GKOS) reported Q3 2020 net sales of $64.8 million, an increase from $58.5 million in Q3 2019. Glaucoma net sales reached $51.9 million, while Corneal Health net sales were $12.9 million. The gross margin stood at approximately 72%, down from 87% in Q3 2019. Operating expenses totaled $59.3 million, with a net loss of $15.7 million or ($0.35) per share. Glaukos has withdrawn its 2020 revenue guidance due to uncertainties from the COVID-19 impact.

Glaukos Corporation (NYSE: GKOS) will release its third quarter 2020 financial results on November 5, 2020, after market close. Management will discuss the results during a conference call at 1:30 p.m. PST (4:30 p.m. EST) on the same day. Interested parties can access the live webcast via the company’s website. Glaukos focuses on innovative technologies for treating glaucoma, corneal disorders, and retinal diseases, having pioneered Micro-Invasive Glaucoma Surgery (MIGS) with products like the iStent.